Improving cancer therapy by non-genotoxic activation of p53
- 1 May 2003
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 39 (8), 1053-1060
- https://doi.org/10.1016/s0959-8049(03)00063-7
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- Therapeutic exploitation of the p53 pathwayTrends in Molecular Medicine, 2002
- Cancer gene therapy: fringe or cutting edge?Nature Reviews Cancer, 2001
- Rescuing the function of mutant p53Nature Reviews Cancer, 2001
- Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumoursNature, 1992
- Mutations in the p53 gene occur in diverse human tumour typesNature, 1989
- Wild-type p53 can inhibit oncogene-mediated focus formation.Proceedings of the National Academy of Sciences, 1989
- The p53 proto-oncogene can act as a suppressor of transformationCell, 1989
- Chromosome 17 Deletions and p53 Gene Mutations in Colorectal CarcinomasScience, 1989
- Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cellsCell, 1979
- T antigen is bound to a host protein in SY40-transformed cellsNature, 1979